ProQR Therapeutics N.V 6-K, filed Jun 30, 2022
ProQR Therapeutics N.V. (PRQR)
About this 6-K
ProQR Therapeutics N.V filed this 6-K on June 30, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2022
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including Zip Code, and Telephone
Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Annual General Meeting Results
On June 30, 2022, ProQR Therapeutics N.V. (“ProQR” or the “Company”) held its 2022 annual general meeting of shareholders in a virtual-only format via videoconference. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:
Agenda Item 4: Adoption of the annual accounts, including the appropriation of net result, for the financial year 2021.
ProQR shareholders approved the adoption of the annual accounts, including the appropriation of net result, for the financial year 2021.
Agenda Item 5: Release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2021.
ProQR shareholders approved the release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2021.
Agenda Item 6: Release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2021.
ProQR shareholders approved the release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2021.
Agenda Item 7: Re-appointment of Supervisory Board member Alison Lawton.
ProQR shareholders approved the re-appointment of Supervisory Board member Alison Lawton.
Agenda Item 8: Re-appointment of Management Board member Daniel de Boer.
ProQR shareholders approved the re-appointment of Management Board member Daniel de Boer.
Agenda Item 9: Appointment of Management Board member Rene Beukema.
ProQR shareholders approved the appointment of Management Board member Rene Beukema.
Agenda Item 10: Appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2023.
ProQR shareholders approved the appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2023.
Agenda Item 11: Amendment of the Compensation Principles for the Supervisory Board.
ProQR shareholders approved the amendment of the Compensation Principles for the Supervisory Board.
Agenda Item 12: Amendment of the Compensation Policy for the Management Board.
ProQR shareholders approved the amendment of the Compensation Policy for the Management Board.
Agenda Item 13: Reverse stock split and amendment of the Articles of Association of the Company.
ProQR shareholders approved the reverse stock split and amendment of the Articles of Association of the Company.
Agenda Item 14: Authorization of the Management Board to issue ordinary shares.
ProQR shareholders approved the authorization of the Management Board to issue ordinary shares.
Agenda Item 15: Authorization of the Management Board to acquire ordinary shares in the capital of the Company.
ProQR shareholders approved the authorization of the Management Board to acquire ordinary shares in the capital of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROQR THERAPEUTICS N.V. | ||
| Date: June 30, 2022 | By: | /s/ Smital Shah |
| Smital Shah | ||
| Chief Business and Financial Officer | ||